Immutep Limited (PRRUF)
USD 0.2
(-26.74%)
USD 0.2
(-26.74%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -37.7 Million AUD | -2711.31% |
| 2023 | 1.44 Million AUD | 176.27% |
| 2022 | -1.89 Million AUD | -205.6% |
| 2021 | 1.79 Million AUD | 111.96% |
| 2020 | -14.98 Million AUD | 8.91% |
| 2019 | -16.45 Million AUD | -123.54% |
| 2018 | -7.35 Million AUD | -404.72% |
| 2017 | 2.41 Million AUD | 135.08% |
| 2016 | -6.88 Million AUD | 2.74% |
| 2015 | -7.07 Million AUD | 25.52% |
| 2014 | -9.5 Million AUD | 13.12% |
| 2013 | -10.93 Million AUD | -819.66% |
| 2012 | 1.52 Million AUD | 0.0% |
| 2011 | - AUD | -100.0% |
| 2010 | 523.73 Thousand AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.11 Million AUD | 0.0% |
| 2024 Q4 | -19.37 Million AUD | 0.0% |
| 2024 FY | -2.26 Million AUD | -256.65% |
| 2023 Q4 | 896.16 Thousand AUD | 0.0% |
| 2023 FY | 1.44 Million AUD | 176.27% |
| 2023 Q2 | 750.33 Thousand AUD | 0.0% |
| 2022 FY | -1.89 Million AUD | -205.6% |
| 2022 Q2 | 1.13 Million AUD | 0.0% |
| 2022 Q4 | -946.33 Thousand AUD | 0.0% |
| 2021 FY | 1.79 Million AUD | 111.96% |
| 2021 Q2 | 1.15 Million AUD | 0.0% |
| 2021 Q4 | 633.02 Thousand AUD | 0.0% |
| 2020 FY | -14.98 Million AUD | 8.91% |
| 2020 Q2 | -4.53 Million AUD | 0.0% |
| 2020 Q4 | -10.45 Million AUD | 0.0% |
| 2019 Q4 | -8.86 Million AUD | 0.0% |
| 2019 FY | -16.45 Million AUD | -123.54% |
| 2019 Q2 | -5.3 Million AUD | 0.0% |
| 2018 Q2 | -410.09 Thousand AUD | 0.0% |
| 2018 FY | -7.35 Million AUD | -404.72% |
| 2018 Q4 | -2.72 Million AUD | 0.0% |
| 2017 Q4 | -2.28 Million AUD | 0.0% |
| 2017 FY | 2.41 Million AUD | 135.08% |
| 2017 Q3 | - AUD | 100.0% |
| 2017 Q2 | -1.11 Million AUD | 0.0% |
| 2016 Q2 | -2.74 Million AUD | 0.0% |
| 2016 FY | -6.88 Million AUD | 2.74% |
| 2016 Q4 | -3.04 Million AUD | 0.0% |
| 2016 Q3 | - AUD | 100.0% |
| 2015 FY | -7.07 Million AUD | 25.52% |
| 2015 Q4 | -3.89 Million AUD | 0.0% |
| 2015 Q2 | -3.72 Million AUD | 0.0% |
| 2014 FY | -9.5 Million AUD | 13.12% |
| 2014 Q4 | -5.53 Million AUD | 0.0% |
| 2014 Q2 | -4.37 Million AUD | 0.0% |
| 2013 Q4 | -6.56 Million AUD | 0.0% |
| 2013 FY | -10.93 Million AUD | -819.66% |
| 2013 Q2 | -5.79 Million AUD | 0.0% |
| 2012 FY | 1.52 Million AUD | 0.0% |
| 2011 FY | - AUD | -100.0% |
| 2010 FY | 523.73 Thousand AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 7915.561% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 9292.605% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 422.098% |
| GB Sciences, Inc. | -624.00 USD | -6042343.429% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -30245.709% |
| Zenith Capital Corp. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -1545814.186% |
| Biomind Labs Inc. | -15.42 Thousand USD | -244355.699% |
| ContraFect Corporation | -154 Thousand USD | -24383.667% |
| CSL Limited | 7.56 Billion USD | 100.499% |
| CytoDyn Inc. | -29 Thousand USD | -129916.714% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | -46.154% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -78030.187% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -110309.508% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 21455.26% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 131.656% |
| SQZ Biotechnologies Company | 9.79 Million USD | 484.979% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 60693.397% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 351.382% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 57464.969% |
| Mesoblast Limited | -35.16 Million USD | -7.214% |
| Marizyme, Inc. | 457.7 Thousand USD | 8337.859% |
| Genus plc | 178.7 Million USD | 121.1% |
| Pharming Group N.V. | 220.1 Million USD | 117.13% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -342671.336% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 49219.797% |
| IMV Inc. | -962.29 Thousand USD | -3818.209% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -9630.258% |
| MultiCell Technologies, Inc. | 49.32 USD | 76449505.921% |
| ONE Bio Corp. | 20.12 Million USD | 287.349% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 193.642% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 233.445% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | -3202.888% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 53964.067% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -761306.442% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 26936.19% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -43728.576% |
| Enzolytics Inc. | 30.7 Thousand USD | 122885.095% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 103.401% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -7228.302% |
| Genscript Biotech Corporation | 409.55 Million USD | 109.206% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 1215601.193% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -425654.822% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -44867.557% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -75309.694% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 3916.353% |
| EV Biologics, Inc. | 48.9 Thousand USD | 77206.027% |
| Q BioMed Inc. | -8988.00 USD | -419402.081% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 492.309% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 185.002% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 344.442% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -38565.689% |
| HST Global, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -18127230.288% |
| Resverlogix Corp. | - USD | Infinity% |
| Cell Source, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 6207.195% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | -5883.586% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -318487.638% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 21455.26% |
| Affymax, Inc. | 1.35 Million USD | 2878.252% |
| Itoco Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 918.248% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -8285.00 USD | -454997.731% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 8478.054% |
| SYBLEU INC | 11.69 Thousand USD | 322473.863% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -11700.946% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -10008.538% |
| Neutra Corp. | 14.33 Thousand USD | 263126.488% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -45881.521% |
| PureTech Health plc | -1.6 Million USD | -2252.143% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -3665.83% |
| IXICO plc | 3.27 Million USD | 1253.053% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -5332.975% |
| Gelesis Holdings, Inc. | -1.79 Million USD | -2005.24% |
| CSL Limited | 7.7 Billion USD | 100.489% |
| Cellectis S.A. | 18 Thousand USD | 209571.372% |